The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2014
Filed:
Jul. 08, 2009
Jjijie Gu, Shrewsubry, MA (US);
Charles W. Hutchins, Green Oaks, IL (US);
Rong-rong Zhu, Southborough, MA (US);
Jianwei Shen, Lake Bluff, IL (US);
Maria C. Harris, Shrewsbury, MA (US);
Eileen Belanger, Northbridge, MA (US);
Anwar Murtaza, Westborough, MA (US);
Edit Tarcsa, Westborough, MA (US);
William B. Stine, Shrewsbury, MA (US);
Chung-ming Hsieh, Newton, MA (US);
Jjijie Gu, Shrewsubry, MA (US);
Charles W. Hutchins, Green Oaks, IL (US);
Rong-rong Zhu, Southborough, MA (US);
Jianwei Shen, Lake Bluff, IL (US);
Maria C. Harris, Shrewsbury, MA (US);
Eileen Belanger, Northbridge, MA (US);
Anwar Murtaza, Westborough, MA (US);
Edit Tarcsa, Westborough, MA (US);
William B. Stine, Shrewsbury, MA (US);
Chung-ming Hsieh, Newton, MA (US);
AbbVie, Inc., North Chicago, IL (US);
Abstract
The present invention encompasses prostaglandin E(PGE) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin Eand neutralize prostaglandin Eactivity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin Eand for inhibiting prostaglandin Eactivity, e.g., in a human subject suffering from a disorder in which prostaglandin Eactivity is detrimental.